Vectura Group Stock

VEC

GB00BKM2MW97

Delayed London S.E. Other stock markets 23:35:22 18/10/2021 HKT			5-day change	1st Jan Change
164.80 ^GBX	-.--%		-.--%	-

31/10/25	Liquidia Technologies, Inc. Enters into an Exclusive Licensing Agreement with Vectura Limited	CI
17/09/24	Molex Asia Holdings Ltd. signed an agreement to acquire Vectura Group plc from Vectura Fertin Pharma, Inc. for £300 million.	CI

on all subscriptions*

Last days

Enjoy this offer

* See conditions under "Our services"

Analysts' recommendations: Vectura Group

27/05/21	VECTURA : Panmure Downgrades Vectura Group To Hold From Buy, Raises PT	MT
22/01/21	VECTURA : Citigroup Downgrades Vectura To Neutral From Buy, Keeps PT	MT

More recommendations

News in other languages: Vectura Group

16/09/21	Résumé des principales informations économiques du jeudi 16 septembre
16/09/21	Les valeurs à suivre aujourd'hui à Wall Street - Jeudi 16 septembre 2021
16/09/21	Philip Morris : offre inconditionnelle sur Vectura Group
16/09/21	Philip Morris International : confirme le rachat de Vectura
16/09/21	USA-Les valeurs à suivre à Wall Street (actualisé)

More news

Managers and Directors: Vectura Group

Manager	Title	Age	Since
Anthony Fitzpatrick CEO	Chief Executive Officer	-	-
Geraldine Venthoye CTO	Chief Tech/Sci/R&D Officer	-	01/06/2016
Robert J Zeitler SEC	Corporate Secretary	-	30/06/2025

Director	Title	Age	Since
Chad Williams BRD	Director/Board Member	53	15/09/2023
Charles Schumacher BRD	Director/Board Member	57	30/06/2025

More insiders

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.

Employees

Sector

More about the company

Market Cap	1B 868M 800M 748M 1.4B 95.49B 1.42B 9.44B 3.68B 46.48B 3.77B 3.69B 161B	P/E Ratio 2019	-27.3x	P/E Ratio 2020	6.2x
Enterprise Value	930M 803M 740M 693M 1.3B 88.42B 1.32B 8.74B 3.41B 43.04B 3.49B 3.42B 149B	EV / Sales 2019	2.8x	EV / Sales 2020	3.49x
Free-Float	-	Yield 2019 *	-	Yield 2020	-

31/10/25	Liquidia Technologies, Inc. Enters into an Exclusive Licensing Agreement with Vectura Limited	CI
17/09/24	Molex Asia Holdings Ltd. signed an agreement to acquire Vectura Group plc from Vectura Fertin Pharma, Inc. for £300 million.	CI
16/04/24	Mundipharma and Vectura Announce Plans to Reformulate Fluticasone Propionate/Formoterol Fumarate	CI
29/12/21	EnBiotix, Inc. announced that it has received $11 million in funding from Vectura Group plc, Cystic Fibrosis Foundation	CI
03/12/21	Philip Morris CEO does not need M&A to hit smoke free goals	RE
03/12/21	REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - THOSE WORRIES THAT PEOPLE WILL LEAVE (BECAUSE OF DEAL) ARE WELL PUT BEHIND US	RE
03/12/21	REUTERS NEXT- PHILIP MORRIS CEO SAYS IN INVESTOR CONFERENCE IN FEB WE WILL HAVE QUALITY TIME TO EXPLAIN THE SOLVABLE OPPORTUNITIES TO INVESTORS WHAT VECTURA AND FERTIN WILL BRING TO PMI	RE
03/12/21	REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - NO SCIENTISTS FROM VECTURA HAVE LEFT CO BECAUSE OF PMI'S ACQUISITION	RE
03/12/21	REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - "I DON’T THINK THERE IS ANYBODY WHO WILL DISAGREE THAT THIS IS A POSITIVELY DRIVEN TRANSFORMATION"	RE
02/12/21	REUTERS NEXT- PHILIP MORRIS CEO SAYS IN INVESTOR CONFERENCE IN FEB WE WILL HAVE QUALITY TIME TO EXPLAIN THE SOLVABLE OPPORTUNITIES TO INVESTORS WHAT VECTURA AND FERTIN WILL BRING TO PMI	RE
02/12/21	REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - THOSE WORRIES THAT PEOPLE WILL LEAVE (BECAUSE OF DEAL) ARE WELL PUT BEHIND US	RE
02/12/21	REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - NO SCIENTISTS FROM VECTURA HAVE LEFT CO BECAUSE OF PMI'S ACQUISITION	RE
02/12/21	REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - "I DON’T THINK THERE IS ANYBODY WHO WILL DISAGREE THAT THIS IS A POSITIVELY DRIVEN TRANSFORMATION"	RE

18/11/21	Vectura : wins Mediscience’s Best Communication Award Published17/11/2021 Read more	PU
15/09/21	Vectura : at Formulation and Delivery UK congress, London 21-22 September Published14/09/2021 Read more	PU
08/09/21	Norges Bank : - Form 8.3 - Vectura Group PLC	PR
01/09/21	Dimensional Fund Advisors Ltd. : Form 8.3 - VECTURA GROUP PLC - Ordinary Shares	AQ
24/08/21	Vectura : Our CDMO expertise in the spotlight Published24/08/2021 Read more	PU

5 years	131.2		176
10 years	59.1		180.88

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/10/21	Will Downie	Fiscal year	Chief Executive Officer	1,311,395	0.2149%
01/10/21	Paul Fry	Fiscal year		159,896	0.0262%
01/10/21	Paul Fry	Fiscal year		81,089	0.0133%

Vectura Group Stock

Stocks

VEC

GB00BKM2MW97

Valuation: Vectura Group

Latest news : Vectura Group

Analysts' recommendations: Vectura Group

Press Releases: Vectura Group

News in other languages: Vectura Group

Course Extremes

Managers and Directors: Vectura Group

Latest insider transactions

Financials

Company Profile

	2019	2020
Net sales	178M 154M 142M 133M 249M 16.95B 253M 1.68B 653M 8.25B 669M 655M 28.56B	191M 165M 152M 142M 266M 18.12B 270M 1.79B 698M 8.82B 715M 700M 30.53B
Net income	-22.1M -19.09M -17.59M -16.46M -30.86M -2.1B -31.33M -208M -80.98M -1.02B -82.94M -81.18M -3.54B	122M 106M 97.42M 91.19M 171M 11.63B 174M 1.15B 448M 5.66B 459M 450M 19.61B
Net Debt	-66.5M -57.44M -52.93M -49.54M -92.85M -6.32B -94.28M -625M -244M -3.08B -250M -244M -10.65B	-74.4M -64.26M -59.21M -55.43M -104M -7.07B -105M -699M -273M -3.44B -279M -273M -11.92B